Williams, P. Mickey

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 294

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 151